Abstracts tagged "SLE"

Abstract Number: 812 • 2015 ACR/ARHP Annual Meeting
SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE
Denis Comte^1,2, Maria P. Karampetsou¹, Katalin Kis-Toth¹, Nobuya Yoshida¹, Julie Solomon¹, Vasileios C. Kyttaris¹ and George C. Tsokos¹, ¹Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Background/Purpose: SLE is a multisystem autoimmune disease that displays quantitative and qualitative deficiencies of regulatory T cells (Treg), notably because of a compromised IL-2 production.…
Abstract Number: 1770 • 2015 ACR/ARHP Annual Meeting
A New Perspective in Extracorporeal Immunotherapy of Systemic Lupus Erythematosus: Dnase I-Based Blood Perfusion Experiment Using Rat Model
Ekaterina Simakova, Andrey Trofimenko, Ilya Gontar and Irina Zborovskaya, Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia
Background/Purpose: DNA, nucleosomes, and other deoxyribonucleoproteins (DNP) are currently believed to be the key autoantigens in SLE. However, these extracellular DNP itself appear to be…
Abstract Number: 1862 • 2015 ACR/ARHP Annual Meeting
Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities
Petra Budde¹, Hans-Dieter Zucht¹, Daniel Chamrad¹, Anna Telaar¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In SLE, early diagnosis, differentiation to other autoimmune diseases and prognostic stratification are still great challenges. Hence, SLE represents an enormous challenge for the…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 734 • 2015 ACR/ARHP Annual Meeting
Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study
Mary Flor Joy Edar, Leonid Zamora, Catherine Macapagal and Sandra V. Navarra, Rheumatology, University of Santo Tomas Hospital, Manila, Philippines
Background/Purpose: This study describes the disease patterns, flare incidence, hospitalizations and causes of mortality in a cohort of Filipino patients with systemic lupus erythematosus (SLE),…
Abstract Number: 817 • 2015 ACR/ARHP Annual Meeting
Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus
Chau-Ching Liu¹, Susan Manzi² and Joseph Ahearn³, ¹Allegheny Singer Research Institute, Pittsburgh, PA, ²Rheumatology, Allegheny Health Network, Pittsburgh, PA, ³Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Accelerated atherosclerotic disease has been widely recognized in patients with SLE. Circulating endothelial cells (CECs) are a rare cell population believed to detach from…
Abstract Number: 1773 • 2015 ACR/ARHP Annual Meeting
Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway
Keigo Ikeda^1,2, Kunihiro Hayakawa², Maki Fujishiro³, Mikiko Kawasaki³, Takuya Hirai^2,4, Shinji Morimoto^2,4, Yoshinari Takasaki⁵ and Iwao Sekigawa^3,4, ¹Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ²Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: We previously reported that Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway-mediated regulation of interferon (IFN) regulatory factor (IRF)-related genes may have an…
Abstract Number: 1867 • 2015 ACR/ARHP Annual Meeting
Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus
Yun Deng¹, Jennifer M. Grossman^1,2, Qiong Fu¹, William J. Martin¹, Judith A. James³, Joan T. Merrill⁴, Diane L. Kamen⁵, Gary S. Gilkeson⁵, Susan A. Boackle⁶, Chaim Putterman⁷, Jane E. Salmon⁸, Vasileios C. Kyttaris⁹, George C. Tsokos⁹, Matthew Quirk¹⁰, Seema Kamble¹, Melissa Barcelona¹, Erika Magdangal¹⁰, Lori Sahakian¹¹, Seung Yoon Lee¹, Tracy Y. Lin¹, Weiling Chen¹, Jennifer M.P. Woo¹², Ornella J. Rullo¹², Deborah K. McCurdy¹², Bevra H. Hahn^13,14, Maureen A. McMahon¹¹, Sang-Cheol Bae¹⁵ and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Rheumatology, UCLA, Los Angeles, CA, ³Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ⁸Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁹Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ¹⁰Division of Rheumatology, Department of Medicine,, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ¹¹Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹²Pediatric Rheumatology, Mattel Children's Hospital, University of California Los Angeles, Los Angeles, CA, ¹³Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹⁴Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA, ¹⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose :Organ damage predicts physical disability and mortality of SLE. Given that men with SLE tend to develop accelerated damage, we selected an X-linked androgen…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…
Abstract Number: 736 • 2015 ACR/ARHP Annual Meeting
Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies
H. Michael Belmont¹, Janet Nwaukoni² and Jill P. Buyon², ¹Hosp for Joint Disease, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: We and others have suggested that complement activation can serve as an initiating signal that increases the thrombosis risk in SLE patients with antiphospholipid antibodies.…
Abstract Number: 820 • 2015 ACR/ARHP Annual Meeting
Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Mikhail Olferiev, David Fernandez, Leila Khalili, Dina Greenman, Mary K. Crow and Kyriakos A. Kirou, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Decreases in peripheral blood levels of complement components of C3 and C4 are associated with SLE and often indicate a lupus flare. The aim…
Abstract Number: 1777 • 2015 ACR/ARHP Annual Meeting
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Li Chun Wang¹, Stuart Perper¹, Kimberly Black¹, Regina Mario¹, Candace Graff^2,3, Dawna Hartman³, Andrew Souers⁴, Steven Elmore⁴ and Lisa Olson^1,3, ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. We report here that continuous daily treatment with 30mpk venetoclax…
Abstract Number: 1870 • 2015 ACR/ARHP Annual Meeting
A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities
Yogita Ghodke-Puranik¹, Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin², Ashima Makol³, Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi Chowdhary⁴, Mark A. Jensen⁵ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, autoimmune disease characterized by autoantibodies to nucleic acids and nucleosomal proteins. The type I interferon pathway is…
Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Maria Boge Lauvsnes¹, Anne Bolette Tjensvoll², Ingeborg Kvivik³, Roald Omdal⁴ and Chaim Putterman⁵, ¹Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ³Reasearch Department, Stavanger University Hospital, Stavanger, Norway, ⁴Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…
Abstract Number: 739 • 2015 ACR/ARHP Annual Meeting
Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Katharine Hickman¹, Laurence S Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: An increasing number of studies have investigated factors that are associated with thrombosis in SLE. However, few have examined risk factors specific for venous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].